PMEF
AKYA

Point72 Middle East FZE’s Akoya BioSciences AKYA Stock Holding History

Point72 Middle East FZE’s Portfolio AKYA Stock Details AKYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,355
Closed -$31K – 59
2023
Q4 		$31K Buy
+6,355
New +$26.4K ﹤0.01% 1332

Other funds holding AKYA

BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Middle East FZE's AKYA Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Akoya BioSciences (AKYA) in Q1 2024, closing a stake of 6,355 shares — an estimated $31K sold.

Point72 Middle East FZE first reported a position in AKYA in Q4 2023 and held it in 1 quarter. The position peaked at $31K in Q4 2023. 68 funds tracked by Wall St. Rank hold AKYA as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Akoya BioSciences position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 6,355 Akoya BioSciences shares in Q1 2024, an estimated $31K.
  • Point72 Middle East FZE first reported a position in Akoya BioSciences in Q4 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Akoya BioSciences position peaked at $31K in Q4 2023.
  • 68 funds tracked by Wall St. Rank held Akoya BioSciences as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.